Kinex Files IND for KX2-391 with the US Food and Drug Administration

Kinex Pharmaceuticals LLC, announced today that the Company has filed its first Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for KX2-391 (KX01), an internally developed small molecule, oral, anticancer product candidate. KX2-391 is a highly selective Src kinase inhibitor that targets the peptide substrate binding site, not the ATP binding site as do all other Src inhibitors commercially available or in development. Because of its unique mechanism of Src inhibition, KX2-391 will be first in class and because of its exceptional selectivity coupled with its robust anti-cancer activity, it will also be potentially best in class.

...

Want to see the full article?

• Purchase this article for only $3.00